US 11,945,815 B2
PTPN11 inhibitors
Philip Jones, Houston, TX (US); Barbara Czako, Bellaire, TX (US); Christopher L Carroll, Houston, TX (US); Pijus Mandal, Sugarland, TX (US); and Jason Cross, Pearland, TX (US)
Filed by NAVIRE PHARMA, INC., Palo Alto, CA (US)
Filed on Jul. 20, 2021, as Appl. No. 17/380,943.
Application 17/380,943 is a continuation of application No. 16/536,923, filed on Aug. 9, 2019, granted, now 11,104,675.
Claims priority of provisional application 62/773,921, filed on Nov. 30, 2018.
Claims priority of provisional application 62/717,588, filed on Aug. 10, 2018.
Prior Publication US 2022/0041594 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61P 35/00 (2006.01); C07D 491/107 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01); C07D 491/107 (2013.01)] 16 Claims
 
1. A compound, represented by the formula:

OG Complex Work Unit Chemistry